Screening for prostate cancer: Is it a service or a disservice?

Postgraduate Medicine

Volumn 100, Issue 3, 1996, Pages 90-102

  Luttge, Scott ^a   Love, Neil ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CONFERENCE PAPER; DIAGNOSTIC TEST; HUMAN; MALE; MASS SCREENING; PRIMARY MEDICAL CARE; PROSTATE CANCER; PROSTATECTOMY; PUBLIC HEALTH; TREATMENT PLANNING;

EID: 0029786621     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1996.09.71     Document Type: Conference Paper

References (5)

1. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 1995;45(1):70-4
2. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273(4):289-94
3. Cupp MR, Oesterling JE. Prostate-specific antigen, digital rectal examination, and transrectal ultrasonography: their roles in diagnosing early prostate cancer. Mayo Clin Proc 1993;68(3):297-306
4. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993;119(9): 914-23
5. Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med 1993;153(22):2529-37